Enclomiphene is a selective estrogen receptor modulator (SERM) and the trans isomer of clomiphene citrate, originally developed for the treatment of ovarian dysfunction in women. Researchers primarily study enclomiphene for its potential role in addressing male hypogonadism, particularly in preserving fertility while increasing testosterone levels. Key findings from recent studies indicate that enclomiphene significantly raises serum testosterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) levels, while maintaining normal sperm concentrations, contrasting with the effects of testosterone replacement therapies. Current research continues to explore enclomiphene's efficacy and safety in various male populations, highlighting its promise as an alternative treatment option for those with secondary hypogonadism.